Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes.

Chou YC, Chung YT, Liu TY, Wang SY, Chau GY, Chi CW, Soucek P, Krausz KW, Gelboin HV, Lee CH, Ueng YF.

J Pharm Sci. 2010 Feb;99(2):1063-77. doi: 10.1002/jps.21866.

PMID:
19593786
3.

Pretreatment with black tea polyphenols modulates xenobiotic-metabolizing enzymes in an experimental oral carcinogenesis model.

Vidjaya Letchoumy P, Chandra Mohan KV, Stegeman JJ, Gelboin HV, Hara Y, Nagini S.

Oncol Res. 2008;17(2):75-85.

4.

Interactive effects of methyl tertiary-butyl ether (MTBE) and tertiary-amyl methyl ether (TAME), ethanol and some drugs: Triglyceridemia, liver toxicity and induction of CYP (2E1, 2B1) and phase II enzymes in female Wistar rats.

Elovaara E, Stockmann-Juvala H, Mikkola J, Gelboin HV.

Environ Toxicol Pharmacol. 2007 Jan;23(1):64-72. doi: 10.1016/j.etap.2006.07.003. Epub 2006 Jul 7.

PMID:
21783738
5.

Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.

Gelboin HV, Krausz K.

J Clin Pharmacol. 2006 Mar;46(3):353-72. Review.

PMID:
16490812
6.

Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.

Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, Degraff LM, Falck JR, Krausz K, Gelboin HV, Morgan JP, Zeldin DC.

Mol Pharmacol. 2004 Dec;66(6):1607-16. Epub 2004 Sep 10.

7.

Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.

Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G.

Eur J Clin Pharmacol. 2004 May;60(3):173-82. Epub 2004 Mar 31.

PMID:
15054565
9.

Monoclonal antibodies to cytochromes P450.

Gelboin HV, Shou M, Goldfarb I, Yang TJ, Krausz K.

Methods Mol Biol. 1998;107:227-37. No abstract available.

PMID:
14577233
10.
11.

Cigarette smoking and secondary smoke in Turkey: effect on placental aryl hydrocarbon hydroxylase (AHH), infant birth weight, and size.

Kutlu T, Gelboin HV, Gozukara EM.

Bull Environ Contam Toxicol. 2002 Dec;69(6):855-62. No abstract available.

PMID:
12428163
12.

4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.

Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ.

J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.

13.

Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.

Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, Gelboin HV.

Drug Metab Dispos. 2001 Nov;29(11):1410-23.

14.

Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases.

Niemelä O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M.

J Hepatol. 2000 Dec;33(6):893-901.

PMID:
11131450
16.

Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.

Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M.

Xenobiotica. 2000 Apr;30(4):327-43.

PMID:
10821163
17.

Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.

Shou M, Lu T, Krausz KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, Gelboin HV.

Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.

PMID:
10771285
18.

Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery.

Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ.

Trends Pharmacol Sci. 1999 Nov;20(11):432-8. Review. No abstract available.

PMID:
10542439
19.

Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene.

Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ.

J Biol Chem. 1999 Aug 20;274(34):23963-8.

20.
21.

Depentylation of [3H-pentyl]methyl-n-amylnitrosamine by rat esophageal and liver microsomes and by rat and human cytochrome P450 isoforms.

Chen SC, Wang X, Xu G, Zhou L, Vennerstrom JL, Gonzalez F, Gelboin HV, Mirvish SS.

Cancer Res. 1999 Jan 1;59(1):91-8.

22.
23.
24.

Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.

Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV.

Pharmacogenetics. 1998 Oct;8(5):375-82.

PMID:
9825829
25.

Further characterization of the expression in liver and catalytic activity of CYP2B6.

Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA.

J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.

26.

Inhibitory monoclonal antibody to human cytochrome P450 2B6.

Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, Gelboin HV.

Biochem Pharmacol. 1998 May 15;55(10):1633-40.

PMID:
9633999
27.

Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam.

Yang TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV, Yang SK.

Biochem Pharmacol. 1998 Mar 15;55(6):889-96.

PMID:
9586962
28.

Effect of phenobarbital on hepatic CYP1A1 and CYP1A2 in the Ahr-null mouse.

Zaher H, Yang TJ, Gelboin HV, Fernandez-Salguero P, Gonzalez FJ.

Biochem Pharmacol. 1998 Jan 15;55(2):235-8.

PMID:
9448747
29.
30.

Inhibitory monoclonal antibodies to human cytochrome P450 2D6.

Krausz KW, Yang TJ, Gonzalez FJ, Shou M, Gelboin HV.

Biochem Pharmacol. 1997 Jul 1;54(1):15-7.

PMID:
9296346
31.

Role of cytochrome P450 enzyme induction in the metabolic activation of benzo[c]phenanthrene in human cell lines and mouse epidermis.

Einolf HJ, Story WT, Marcus CB, Larsen MC, Jefcoate CR, Greenlee WF, Yagi H, Jerina DM, Amin S, Park SS, Gelboin HV, Baird WM.

Chem Res Toxicol. 1997 May;10(5):609-17.

PMID:
9168260
32.

Toluene metabolism by cDNA-expressed human hepatic cytochrome P450.

Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T.

Biochem Pharmacol. 1997 Feb 7;53(3):271-7.

PMID:
9065730
33.

Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone.

Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV.

Carcinogenesis. 1997 Jan;18(1):207-14.

PMID:
9054608
35.

Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz[a]anthracene.

Shou M, Korzekwa KR, Krausz KW, Buters JT, Grogan J, Goldfarb I, Hardwick JP, Gonzalez FJ, Gelboin HV.

Mol Carcinog. 1996 Dec;17(4):241-9.

PMID:
8989918
36.

Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes.

Shou M, Krausz KW, Gonzalez FJ, Gelboin HV.

Carcinogenesis. 1996 Nov;17(11):2429-33.

PMID:
8968059
37.

Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1.

Gelboin HV, Goldfarb I, Krausz KW, Grogan J, Korzekwa KR, Gonzalez FJ, Shou M.

Chem Res Toxicol. 1996 Sep;9(6):1023-30.

PMID:
8870991
38.

Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.

Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ.

Pharmacogenetics. 1996 Aug;6(4):291-6.

PMID:
8873215
39.

Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450.

Shou M, Krausz KW, Gonzalez FJ, Gelboin HV.

Arch Biochem Biophys. 1996 Apr 1;328(1):201-7.

PMID:
8638931
40.

Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine.

Pellinen P, Stenbäck F, Kojo A, Honkakoski P, Gelboin HV, Pasanen M.

Hepatology. 1996 Mar;23(3):515-23.

PMID:
8617431
41.

Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A.

Omar RF, Gelboin HV, Rahimtula AD.

Biochem Pharmacol. 1996 Feb 9;51(3):207-16.

PMID:
8573185
42.

The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives.

Gut I, Nedelcheva V, Soucek P, Stopka P, Vodicka P, Gelboin HV, Ingelman-Sundberg M.

Arch Toxicol. 1996;71(1-2):45-56.

PMID:
9010585
43.

Immunohistochemical properties of dipyrone-induced cytochromes P450 in rats.

Kraul H, Pasanen M, Sigusch H, Stenbäck F, Park SS, Gelboin HV, Pelkonen O.

Hum Exp Toxicol. 1996 Jan;15(1):45-50.

PMID:
8845208
44.

Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4.

Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, Shou M.

Biochem Pharmacol. 1995 Nov 27;50(11):1841-50.

PMID:
8615863
46.

Inhibition of benzo[a]pyrene metabolism by insulin, FITC-insulin and an FITC-insulin-antibody conjugate in the human hepatoma cell line HepG2.

Polzer RJ, Coffing SL, Marcus CB, Park SS, Gelboin HV, Baird WM.

Chem Biol Interact. 1995 Aug 18;97(3):307-18.

PMID:
7671346
47.

Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

Crespi CL, Steimel DT, Penman BW, Korzekwa KR, Fernandez-Salguero P, Buters JT, Gelboin HV, Gonzalez FJ, Idle JR, Daly AK.

Pharmacogenetics. 1995 Aug;5(4):234-43.

PMID:
8528270
48.

Different contributions of cytochrome P450 2E1 and P450 2B1/2 to chloroform hepatotoxicity in rat.

Nakajima T, Elovaara E, Okino T, Gelboin HV, Klockars M, Riihimäki V, Aoyama T, Vainio H.

Toxicol Appl Pharmacol. 1995 Aug;133(2):215-22.

PMID:
7645016
49.

Aryl hydrocarbon (Ah) receptor-independent induction of Cyp1a2 gene expression by acenaphthylene and related compounds in B6C3F1 mice.

Chaloupka K, Santostefano M, Goldfarb IS, Liu G, Myers MJ, Tsyrolv IB, Gelboin HV, Krishnan V, Safe S.

Carcinogenesis. 1994 Dec;15(12):2835-40.

PMID:
8001243
50.

Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450.

Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T.

Chem Res Toxicol. 1994 Nov-Dec;7(6):891-6.

PMID:
7696548

Supplemental Content

Loading ...
Support Center